Explore our primary range of commercial active pharmaceutical ingredients, high-purity synthetic peptides, and advanced intermediate compounds manufactured under strict international quality standards.
Orlistat, a potent hydrogenated derivative of lipstatin isolated from Streptomyces toxytricini, stands as one of the most clinically validated non-systemic anti-obesity therapeutics in global pharmaceutical history. As a reversible inhibitor of gastric and pancreatic lipases, Orlistat exerts its therapeutic mechanism within the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of lipases. This reaction prevents the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides, resulting in an unabsorbed fat excretion rate of approximately 30% of ingested dietary lipids.
Unlike systemic weight-management agents (such as GLP-1 receptor agonists or centrally acting sympathomimetics), Orlistat possesses minimal systemic absorption (<1% systemic bioavailability), rendering its safety profile exceptionally robust. This localized GI mechanism reduces systemic side effects while presenting unique formulation challenges regarding gastrointestinal tolerability, particle dispersion, and enteric pellet coating consistency.
In today's global commercial market, the demand for high-quality Orlistat capsule manufacturers has accelerated due to dual market dynamics: the expansion of Over-The-Counter (OTC) 60mg dosage regimens and prescription-strength (Rx) 120mg dosage formulations. Global procurement managers and pharmaceutical brand owners face strict scrutiny regarding impurity profiles (specifically Impurity A, B, and C as defined by USP/EP monographs), polymorph stability, and dissolution kinetics under variable intestinal pH conditions.
Orlistat acts locally in the gastrointestinal tract without suppressing central nervous system pathways, ensuring high long-term patient compliance and predictable metabolic profiles.
With global adult obesity rates exceeding 1 billion individuals, Orlistat remains the gold-standard oral lipase inhibitor for both OTC wellness platforms and clinical therapies.
Modern pharmaceutical buyers are transitioning from standard powder fill to micro-pelletized enteric-coated formulations to optimize release timing and reduce gastrointestinal distress.
The commercial production of high-grade Orlistat API and finished dosage forms (FDF) demands advanced chemical synthesis, purification technology, and precise temperature-controlled processing due to the low melting point of Orlistat (approximately 44°C to 50°C). Gentolex, utilizing state-of-the-art cGMP certified facilities spanning an overall factory construction area of 250,000 square meters, provides the infrastructure required to meet rigid global requirements.
China's mature chemical synthesis ecosystem offers unequaled backward integration for key raw materials and intermediates required in Orlistat synthesis. Gentolex leverages high-capacity industrial fermenters, automated crystallization systems, and low-temperature fluid bed granulators. This continuous process control reduces batch-to-batch variability while cutting unit production costs by 25% to 40% compared to Western manufacturing hubs.
Operating strictly under ICH Q7 and cGMP frameworks, every batch of Orlistat Capsules undergoes rigorous analytical characterization, including High-Performance Liquid Chromatography (HPLC), Gas Chromatography-Headspace (GC-HS) for residual solvents, and differential scanning calorimetry (DSC) for polymorph verification.
| Parameter | OTC Grade Specification (60mg) | Prescription Grade Specification (120mg) | Analytical Method |
|---|---|---|---|
| Active Ingredient Purity | 99.0% – 101.5% (Anhydrous Basis) | 99.0% – 101.5% (Anhydrous Basis) | HPLC Assay |
| Dosage Form | Hard Gelatin / HPMC Capsule (Size 2 or 1) | Hard Gelatin / HPMC Capsule (Size 1 or 0) | Visual Inspection |
| Formulation Type | Micro-pelletized / Powder Fill | Enteric-Coated Pellets / Granules | Particle Size Analyzer |
| Dissolution Rate | >85% within 30 minutes in SDS Medium | >80% within 45 minutes in SDS Medium | USP <711> Apparatus 2 (Paddle) |
| Related Substances (Individual) | Impurity A ≤ 0.15%, Impurity B ≤ 0.15% | Impurity A ≤ 0.10%, Impurity B ≤ 0.10% | HPLC-UV |
| Water Content (Karl Fischer) | ≤ 0.5% | ≤ 0.3% | USP <921> Method Ic |
| Heavy Metals / Residues | Lead ≤ 0.5 ppm, Cadmium ≤ 0.5 ppm | Heavy Metals ≤ 10 ppm total | ICP-MS |
Gentolex’s overarching goal is to create opportunities connecting the global pharmaceutical market with reliable services, guaranteed product excellence, and cost-effective supply chain solutions. To date, Gentolex Group has established active client networks across more than 10 countries, featuring specialized operational representatives and logistics bases in key markets including Mexico and South Africa.
An overall factory construction area of 250,000 square meters under international standards to offer flexible, scalable, and cost-effective synthesis solutions.
Gentolex offers an extensive range of APIs and intermediates with cGMP standards. Complete regulatory documents and certificates are provided to global clients.
Turnkey Finished Dosage Form (FDF) license-out models, micro-encapsulation technologies, and customized oral drug delivery research and development.
End-to-end customized supply chain management, audit support, and centralized sourcing for international pharmaceutical companies.
Procurement strategies for Orlistat capsules vary significantly depending on regulatory environments, distribution networks, and end-user market positioning. Modern pharmaceutical companies require flexible OEM/ODM manufacturing partnerships that can adapt to localized requirements.
Emphasis on 60mg strength, low-dose daily administration packaged in tamper-evident Alu-Alu blister packs or high-density polyethylene (HDPE) bottles with child-resistant caps. Strict adherence to nitrosamine impurity limits and EDQM CEP certifications is mandatory.
High growth in 120mg prescription capsules often prescribed alongside anti-diabetic formulations or cardiovascular therapy programs. Regional distributors require localized regulatory support, CTD-format dossiers, and bioequivalence (BE) comparative study protocols.
Private-label digital healthcare providers require small MOQs, customized branding, vegetarian HPMC capsule shell options, and stability-tested multi-ingredient co-packaging formats for holistic weight management subscriptions.
Due to Orlistat's low melting point, improper processing temperatures during granulation or encapsulation can lead to polymorphism conversion, sticking, or thermal degradation. Gentolex employs proprietary cold-melt extrusion and fluid-bed micro-pellet encapsulation techniques. This protects the active substrate, guarantees zero thermal stress during filling, and yields consistent 24-month stability even in humid tropical zones (Zone IVb).
Comprehensive answers to common technical, manufacturing, and regulatory inquiries submitted by pharmaceutical buyers, regulatory affairs officers, and supply chain directors.
Stay updated with Gentolex's cutting-edge developments in peptide synthesis, metabolic research APIs, and pharmaceutical manufacturing technology.
Browse our secondary catalog of specialized chemical intermediates, custom synthesis building blocks, and peptide formulations available for bulk commercial procurement.
